BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28059154)

  • 1. ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
    Zhang W; Chen Z; Chen L; Wang F; Li F; Wang X; Fu L
    Sci Rep; 2017 Jan; 7():40064. PubMed ID: 28059154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
    Wang F; Liang YJ; Wu XP; Su XD; Fu LW
    Chin J Cancer; 2012 Mar; 31(3):150-8. PubMed ID: 22360854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
    Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
    Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
    Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
    Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Evaluation of Multidrug Resistance via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.
    Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
    Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.
    Wang DS; Patel A; Shukla S; Zhang YK; Wang YJ; Kathawala RJ; Robey RW; Zhang L; Yang DH; Talele TT; Bates SE; Ambudkar SV; Xu RH; Chen ZS
    Oncotarget; 2014 Jun; 5(12):4529-42. PubMed ID: 24980828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine D
    Hussein N; Amawi H; Karthikeyan C; Hall FS; Mittal R; Trivedi P; Ashby CR; Tiwari AK
    Cancer Lett; 2017 Jun; 396():167-180. PubMed ID: 28323029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
    Zhang GN; Zhang YK; Wang YJ; Barbuti AM; Zhu XJ; Yu XY; Wen AW; Wurpel JND; Chen ZS
    Pharmacol Res; 2017 May; 119():89-98. PubMed ID: 28131876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors.
    Ye GJ; Cai CY; Dong XD; Wu ZX; Teng QX; Wang JQ; Chen ZS; Wang B
    Bioorg Chem; 2023 Jun; 135():106481. PubMed ID: 36966672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
    Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
    Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.
    Wang DS; Patel A; Sim HM; Zhang YK; Wang YJ; Kathawala RJ; Zhang H; Talele TT; Ambudkar SV; Xu RH; Chen ZS
    J Cell Biochem; 2014 Aug; 115(8):1381-91. PubMed ID: 24939447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
    Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance:
    Li J; Kumar P; Anreddy N; Zhang YK; Wang YJ; Chen Y; Talele TT; Gupta K; Trombetta LD; Chen ZS
    Oncotarget; 2017 Nov; 8(55):93785-93799. PubMed ID: 29212189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.
    Gao HL; Cui Q; Wang JQ; Ashby CR; Chen Y; Shen ZX; Chen ZS
    Front Pharmacol; 2023; 14():1235285. PubMed ID: 37521473
    [No Abstract]   [Full Text] [Related]  

  • 20. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
    Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS
    Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.